Aims To assess how far the greater effectiveness of varenicline over nicotine replacement therapy (NRT) is moderated by characteristics of the smokers or setting in clinical practice. Design We used observational data from 22 472 treatment episodes between 2013 and 2016 from smoking cessation services in England to assess whether differences between varenicline and NRT were moderated by a set of smoker and setting characteristics: these included level of social deprivation, age, gender, ethnic group, nicotine dependence and treatment context. From the above, 15 640 episodes were analysed in relation to 4-week quit and 14 273 episodes at 12 weeks. All two-way interactions involving pharmacotherapy were fitted in addition to the main effects and a parsimonious model identified using a backwards stepwise selection procedure. Setting England Participants Clients of smoking cessation service (number of individuals in 4-week quit analysis = 15 640). Measurements Four-week carbon monoxide-validated (primary outcome) and 12-week selfreported (secondary outcome) quit success/failure. Findings At both follow-up points, varenicline was associated with higher success rates overall [P < 0.001 at both 4 and 12 weeks; adjusted odds ratio (OR) varenicline versus NRT = 1.82 (95% confidence interval (CI) = 1.61, 2.06) and 2.58 (95% CI = 2.26, 2.94) at 4 and 12 weeks, respectively]. At 12 weeks, the relative benefits of varenicline were found to be influenced by the setting in which advice was provided [P < 0.001 for interaction pharmacotherapy × setting; adjusted odds ratio for varenicline × pharmacy setting = 0.53 (95% CI = 0.42, 0.69) and for varenicline × general practice (GP) setting = 0.79 (95% CI = 0.64, 0.98) against a baseline of 1 for varenicline × community setting]. The same trends were evident at 4 weeks, but this did not translate to statistical significance. There was inconclusive evidence for moderating effects of other variables. Conclusions Varenicline use was associated with higher smoking cessation rates than nicotine replacement therapy in routine clinical practice, irrespective of a wide range of smoker characteristics, but the difference was less in certain intervention settings, most notably pharmacy but also GP practice, compared with community setting.
INTRODUCTION
Smoking cessation services are provided in many countries around the world, given the awareness of the public health burden associated with high levels of smoking in the population [1] . A range of factors show association with higher success rates in these kinds of services [2] [3] [4] . Among these is the use of varenicline (Chantix) in contrast to nicotine replacement therapy (NRT). However, it is not clear how far the relative benefits of varenicline are influenced by characteristics of smokers or aspects of service delivery. This study assessed the impact on treatment effect of a range of covariates recorded at the individual, temporal and service levels.
The UK has a well-established network of smoking cessation services [5] . According to National Institute for Healthcare Excellence (NICE) and National Centre for Smoking Cessation Training (NCSCT) guidelines [6, 7] smoking cessation services provide a programme of counselling sessions with accredited advisers supplemented by tailored pharmacotherapy, using treatments which have shown efficacy in relation to placebo/no treatment in clinical trials. Clients are offered two forms of NRT, including skin patches and an oral product [8] , although they may opt for one only if, for example, there are concerns over an existing skin condition in relation to skin patches. The use of 'combination' NRT has been found to yield improved success rates relative to 'single use' NRT [2, 9] . Other treatments are available in the form of varenicline and bupropion (Zyban). Varenicline has been found to yield higher quit rates than other treatments [10] , although combination NRT was estimated to have near parity in a network meta-analysis [11] . The performance of varenicline in a real-world setting is less well understood, although some evidence exists to suggest that the benefits seen in randomized controlled trials (RCTs) can be replicated in a clinical setting [12, 13] .
It is important to provide treatments for smokers that are tailored to their needs. It may be hypothesized that the effectiveness of pharmacotherapy is, in part, dependent upon client characteristics (age, gender, level of dependence). Such effects have been observed in relation to varenicline in the treatment of alcohol dependence [14] . While the benefits of pharmacotherapy with respect to smoking cessation are well known, the potential moderating effects of other variables are less well understood.
We used data recorded on clients registered with Quit 51 [15] , a provider of smoking cessation services in England, to test whether the increased quit rates expected with varenicline versus NRT are moderated by other factors (such as age, gender, ethnic group and features of service provision). An earlier analysis of data from Quit 51 focused on interactions with gender including treatment [16] . The current work takes in approximately 6 months of further data (up to September 2015 in previous analysis, now up to March 2016) in addition to records from seven extra regions, for which data were not available in this earlier analysis. A number of new covariates/factors were considered in analysis, including the Fagerström Test for Nicotine Dependence (FTND), the Index of Multiple Deprivation (IMD) and ethnicity. The size of the master data set in the current analysis was 22 472, in comparison to 11 394 in the aforementioned work.
METHODS

Participants, design and setting
We used data recorded by Quit 51 on clients using the service between March 2013 and March 2016 within the following 11 English regions: Leicester, Lincoln, Sandwell, Solihull, Stoke, Surrey, East Sussex, Telford & Wrekin, Walsall, West Cheshire and Worcester. At the outset this comprised 22 472 observations, but this number was reduced (with the omission of two of the original regions) as a result of some records being omitted prior to statistical analysis (Fig. 1) .
Data recorded by Quit 51 are wide-ranging, including client-level information (age, gender, metrics relating to tobacco dependence, etc.), details on support provided [pharmacotherapy, whether counselling was on a group basis at a general practitioner (GP) or pharmacy or one-to-one, etc.], information on sessions attended (date, duration, etc.) in addition to measures of the success/failure of the quit attempt. The primary motivation of this work was to identify the relationship between pharmacotherapy and quit success (at 4 and 12 weeks) and to investigate whether this relationship was moderated by other covariates. Awareness of such relationships may be informative in deciding on individual treatment regimens for users of smoking cessation services.
Measures
Our primary outcome measure was carbon monoxide (CO)-validated quit [17] , in line with National Health Service (NHS) guidelines at 4 weeks, and this was supported by analysis of self-reported quit at 12 weeks (CO readings were only taken at the 4-week time-point). A number of additional variables were extracted or derived from master data, namely: gender, age at quit date (four categories: 13-19 years, 20-39 years, 40-59 years, 60 years and above) and pharmacotherapy (NRT/varenicline), intervention setting-a categorical variable describing the setting in which client met with practitioner for advisory sessions [the original categories are described elsewhere [18] , but in this work these were reduced to community, GP practice, pharmacy, Stop Smoking Service (SSS) and other], year, yearly quarter (January/February/March = 1, April/May/June = 2, July/August/September = 3, October/November/December = 4), ethnic group (six categories derived from original data-white; British and Irish, white; other, Asian, black, other, unknown) and nicotine dependence based on the Fagerström Test for Nicotine Dependence (FTND) [19] , whereby a higher score denotes greater dependence.
Social deprivation was assessed using the IMD [20] , a deprivation score mapped to postcode and scored on a scale of 1-10 inclusive, with lower scores indicating greater deprivation. In order to facilitate interpretation when talking of a deprivation effect, these scores were inverted so that 1 = least deprived/most affluent area, with increasing score indicating a greater degree of deprivation (maximum = 10). Summary statistics for both deprivation and FTND are presented for each individual score (i.e. as a categorical variable), but in statistical analyses these were treated as continuous variables.
Data preparation
Preliminary restrictions were applied to the master data set. Instances where bupropion had been prescribed were removed, as the number (n = 80) was considered too low to be able to make a meaningful comparison with the other treatments. Clients recorded as pregnant were also left out of analysis. In some instances, more than one treatment was recorded as having been prescribed. These cases were removed, as it was not possible to compare treatment effect in addition to there being uncertainty as to whether this information had been recorded correctly. Cases where age was recorded outside the range 13-89 years inclusive were also removed, as it was considered anything outside this range may have been recorded erroneously. The above restrictions gave rise to a data set of 20 463 observations (data set 2, Fig. 1 ), which was used for the derivation of summary statistics.
In addition to the main analysis, frequencies are presented in the subgroups prescribed (i) NRT and (ii) varenicline for a group of factors which were not considered in regression models. Included here are the binary variables 'live with other smokers (no/yes)' and 'live with children (no/yes)'. Furthermore, a number of morbidities were identified from the variable 'medical condition' (text field consisting of a list of medical conditions), which may have influenced choice of treatment. From these, three binary variables were derived: psychological condition (where original field included 'anxiety disorder', 'schizophrenia', 'depression', 'mental illness', 'manic-depressive disorder' or 'eating disorder'); heart condition [from 'angina', 'heart disease', 'heart attack', 'heart failure', 'acute cardiovascular event within the last 4 weeks' or 'coronary heart disease (CHD)'] and lung condition [from 'bronchitis', 'emphysema', 'collapsed lung', 'chronic obstructive pulmonary disease (COPD)' or 'persistent cough or breathlessness']. While these figures may point to imbalance in the two treatment groups, there was uncertainty as to the robustness in the recording of these fields, and none of these variables were included in regression models.
Four-week analysis
Further sequential restrictions were applied before analysis of quit at 4 weeks. Specifically (i) removal of observations where the quit date fell after 31 January 2016, (ii) omission of records where the intervention setting field is empty, (iii) retention of either the first chronological observation where all analytical data were available or the first chronological observation if no such 'comprehensive' record was available. The first of these was carried out to ensure as far as possible that 4-week quit information was not incomplete, i.e. that the client was not in the middle of a cessation attempt at the time of data compilation. The final step ensured that each individual contributed one record only, as there was a small degree of client replication, as can be ascertained from Fig. 1 .
Analyses
Analysis was carried out on 4-week CO-validated quit (0/ 1) using a generalized linear mixed model (GLMM) procedure [21] . Explanatory variables fitted were: gender, age, pharmacotherapy, intervention setting, year, yearly quarter, ethnic group, IMD and FTND. A logit transform was applied to the response variable (4-week quit) and dispersion fixed at 1. The region where the client was based was incorporated as an unstructured random effect. A backwards stepwise procedure was applied, starting with a model including all the above explanatory variables as main effects and all two-way interactions involving pharmacotherapy and the other explanatory variables. At each step, the main effect/interaction with the highest P-value (based on χ 2 Wald tests) was identified and removed from the model if above an a priori threshold of 0.05. This process was concluded where all remaining effects had P < 0.05. For ease of interpretation, three-way interactions were not considered, but the possibility of their existence cannot be ruled out (or at higher levels) and the final model selected should not be interpreted as the 'best among all possible models'. Main effects were not considered for removal until interactions involving the relevant variable had been eliminated.
Missing data
By default, a complete-case analytical approach was adopted. As data were missing to varying degrees for a number of variables in the model, the de-facto size of the data set was reduced accordingly. The extent of missing data in some cases was sufficient to potentially undermine the generalizability of the results. The variables identified as missing a significant level of data were (i) pharmacotherapy, (ii) FTND and (iii) IMD, as can be ascertained from Table 1 .
In order to address concerns over possible consequences in the results arising from missing data, the optimal model identified from the original analysis was repeated after data were imputed in respect of the three variables listed above. Values were imputed through regression based on the following explanatory variables: age, gender, occupation, ethnicity and intervention setting. This process was repeated three times in order to allow for uncertainty in the imputation process and from these, averages were derived of parameter estimates and Wald statistics according to a multiple imputation prescription [22] . Details on the imputation are provided in Supporting information, File 1. Regression results from the optimal model identified were compared between (i) the original data set and (ii) the same supplemented with imputed data as described above. Subject to reasonable agreement in this regard, results and subsequent inference were based on results arising from analysis of imputed data. For the purposes of comparison, the results from original complete-case analyses are presented in Supporting information, File 2.
It was anticipated that the inclusion of the teenage subgroup may serve to distort the results, as this group is atypical in certain respects within SSS in addition to the fact that varenicline is not prescribed to those below the age of 18. The analysis was thus rerun without this age group, but it was found that relations for all variables, both in terms of significance and effect size, were preserved within small margins of difference.
The same procedure was repeated for analysis of selfreported quit at 12 weeks, except that the cut-off date used for inclusion was now 9 December 2015. All analyses were carried out in GenStat version 18.0 [23] . Table 1 shows the frequencies of records in the different subgroups for key variables, in addition to the frequency and percentage of varenicline prescription using the sample that was followed-up at 4 weeks. Table 2 gives the frequencies of subgroups of potentially influential factors which were not included in analysis.
RESULTS
With respect to the analysis of the 4-week CO-validated quit, the selected model retained all main effects except ethnic group (and by extension the interaction between ethnic group and treatment). Most of these translated to significant effects when imputed data were included in analysis, except for (i) gender, (ii) treatment × intervention setting and (iii) treatment × FTND, although the direction of these effects was the same in both cases. Model parameters for the analysis of supplemented data at this time-scale are provided in Table 3 . Clients using varenicline were significantly more likely to quit than those using NRT [adjusted odds ratio (OR) for a successful quit and 95% confidence interval (CI) for varenicline versus NRT = 1.82 (1.61-2.06)]. The odds of a successful quit at 4 weeks was found to improve progressively with age group. Clients who were provided with counselling in a community setting had a higher quit rate than all other categories, and a significantly higher OR than all except the 'other' category. The probability of a successful quit was observed to decrease with baseline tobacco dependence and people living in deprived areas were less likely to quit than those in more affluent areas (OR and CI below 1 in both instances; see Table 3 ). Although the overall quit rate at 12 weeks was lower than at 4 weeks (mean quit rate was 56.0 and 28.8% for 4 and 12 weeks, respectively), the overall pattern in terms of ORs at 12-week quit (Table 4) were broadly similar to the above, with a few notable exceptions. The set of variables identified by initial complete-case backwards stepwise regression was the same as for 4 weeks, except for the removal of the interaction between treatment and dependence (FTND). On this occasion, all effects found significant at complete-case analysis were also found to be significant when analysis was repeated on supplemented data. At this time interval, significant differences were found among the levels associated with the interaction between treatment and setting (Table 4 ). This manifested itself through an elevated OR when varenicline was used in conjunction with community setting (this combination was fixed as a reference with an OR of 1, whereas all other combinations involving varenicline were estimated at less than unity), and consideration of the corresponding CIs indicates that this difference was significant in relation to varenicline in conjunction with (i) pharmacy and (ii) GP setting categories.
DISCUSSION
In an analysis of data on clients using a smoking cessation service, varenicline use was found to improve the odds of a successful quit relative to NRT and furthermore, the magnitude of this phenomenon was found to depend upon the setting in which counselling was provided when quit was measured at 12 weeks. In contrast to much of the research in this area, the data originate from a real-world setting where we might expect these effects to be attenuated in relation to those observed in the idealized environment of scientific trials [24] . Table 4 Percentage quit rate (for categorical variables), model coefficients (both for main effects only and full models), odds ratios (OR) (adjusted for model covariates) and significance test results for all main effects and interactions included in the optimal generalized linear mixed model (GLMM) at 12 weeks after quit date (self-reported quit). Model results are based on analyses of supplemented data incorporating imputed values (n = 14 273). Nicotine replacement therapy was prescribed almost three times more often than varenicline. Furthermore, men were prescribed varenicline more often than women. This difference cannot be attributed to non-use of this treatment among pregnant women [8] , as records associated with this subgroup were removed from the data set before analysis. Prescription of varenicline is not currently recommended the under-18s, and this is reflected in the low rate of use in the youngest age group. While overall there were more female users of the service, there were slightly more males than females in the teenage group, which may have influenced results (although gender was controlled for in analysis).
The difference in quit rate between the two treatments presented here is striking, and of a greater magnitude than that reported elsewhere at the same [25] and different points in time [26] . Comparison of quit rates at specific times is complicated by the fact that the agreed quit date coincides with the start of treatment with respect to NRT, but is fixed 8-14 days after start of treatment for those using varenicline. Therefore, there tends to be a longer gap between initial registration and 4-week quit date for varenicline users. This difference in the schedule could potentially influence estimates of treatment effect in unforeseen ways. For example, the extended period between registration and scheduled follow-up dates could, hypothetically, increase the risk of dropout in the intervening period (although there is no evidence to support this idea here, as the cessation rate is higher in varenicline users).
The chance of quit success was also found to be influenced by the session setting, with the highest levels of success seen in relation to community setting at 4 weeks, although this did not emerge as the 'best' setting at 12 weeks. At both 4 and 12 weeks, GP practice fared worse than community setting. The observation that men have a greater chance of quitting than women has been reported elsewhere [27, 28] , as has the link between socio-economic deprivation and low quit rates [29] [30] [31] . Statistical analysis of the initial data (pre-imputation) suggested the presence of interactions between pharmacotherapy and (i) intervention setting and (ii) tobacco dependence at 4 weeks and then intervention setting only at 12 weeks. However, these effects were no longer found to be statistically significant at 4 weeks once imputed data were included. The interaction between treatment and setting was significant at 12 weeks after including the additional data, and it was notable that at both time-points the benefit of varenicline was most diminished in conjunction with pharmacy setting. The low quit rate associated with varenicline in conjunction with pharmacy suggests that more intensive support may be required for clients within this treatment pathway in order for the effects of this medication to be optimized.
In an age where the internet is increasingly accessible, there may in future be greater emphasis on online smoking cessation services [32] , which have been found to increase quit rates, especially in conjunction with medication such as varenicline [28] . This may represent an appealing option for a younger age group, who have a high level of engagement with internet media, and under the current prescription do not achieve as high quit rates as older age groups.
Even allowing for the significant interactions, varenicline was associated with higher quit rates across the different levels for all factors. Thus, while there may be counter-arguments to prescribing varenicline to individuals where there is concern over severity of side effects or possible health consequences (e.g. in the case of teenage smokers) there is no evidence here to suggest that NRT will outperform varenicline in any of these subgroups in enhancing cessation rates.
Although not included in analysis, summary statistics indicate a greater tendency to prescribe NRT rather than varenicline to clients diagnosed with a psychological condition (but not so obviously in relation to other additional factors considered with the possible exception of smokers living with children). This may have had some bearing on the results, although the number of clients in this group is small and the discrepancy in frequency not great (approximately 4%). With the data being observational in nature, the potentially distorting effects of covariates, both measured and unmeasured, cannot be ignored, and further evidence from similar analysis of real-life data collected elsewhere would be valuable in drawing conclusions regarding treatment effects and associated moderators.
There are likely to be interaction effects in relation to a range of variables in addition to those considered here; for example, gender and financial strain, as identified by Reitzel et al. [33] . This provides scope for further research, both through RCTs and observational cohorts. This could also incorporate further experimentation around an optimal regimen for the various pharmaceutical agents. For example, Hajek et al. [34] observed that both quit success and a number of measures recorded in relation to nicotine withdrawal discomfort showed favourable results when smokers were preloaded with varenicline for 4 weeks before the quit date, a period longer than the current prescription in the United Kingdom of 2 weeks. It would also be instructive to learn how such variations in medication regime are moderated (if at all) by other factors.
CONCLUSIONS
In an analysis of data from a smoking cessation service, varenicline was found to outperform NRT as an aid to cessation, men quit with higher probability than women and the percentage of successful quits increased with age. The setting for counselling was also found to influence the chance of quitting. Furthermore, a significant interaction was observed 12 weeks after quitting between (i) pharmacotherapy and (ii) setting such that varenicline was found to be least effective in conjunction with pharmacy setting. Notwithstanding interactions, varenicline was found to enhance quit rates relative to NRT across all subgroups, suggesting a generalized effect. Given that these results are based on observational data, the potentially distorting effects of covariates, both measured and unmeasured, cannot be ignored, and further evidence from independent data would be valuable.
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Table S1
Model coefficients and P-values for all explanatory variables in statistical models for (i) Fagerström Test for Nicotine Dependence (FTND), (ii) Index of Multiple Deprivation (IMD), (iii) nicotine replacement therapy (NRT)/varenicline treatment on main data set. The first two models were linear regressions and the third was a logistic regression and the coefficients should be interpreted accordingly. Table S2 Percentage quit rate (for categorical variables), model coefficients (both for main effects only and full model), odds ratios (adjusted for model covariates) and significance test results for all main effects and interactions included in the optimal Generalized Linear Mixed Model (GLMM) at 4 weeks after quit date. Model results are based on analyses of original data not including imputed values (n = 8572).
